APGE · ISSUER CIK 1974640
Apogee Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 8 Apogee Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $738K of sales on SEC Form 4.
↗8 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 1 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$738KInsider selling
−$738KNet open-market
Sep 3, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 202617:30 | Sep 3, 2026 | APGE | Director · +3 joint | D · To issuer | — | −443,187 | 0 | -100% | — | ||
| Sep 3, 202616:39 | Sep 3, 2026 | APGE | Director | D · To issuer | — | −20,000 | 0 | -100% | — | ||
| Sep 3, 202616:39 | Sep 3, 2026 | APGE | Director | D · To issuer | — | −34,824 | 0 | -100% | — | ||
| Sep 3, 202616:39 | Sep 3, 2026from Sep 2, 2026 | APGE | Chief Medical Officer | D · To issuer | $1.10 | −168,498 | 0 | -100% | $186K | ||
| Sep 3, 202616:39 | Sep 3, 2026 | APGE | Director | D · To issuer | — | −34,824 | 0 | -100% | — | ||
| Sep 3, 202616:39 | Sep 3, 2026 | APGE | Chief Financial Officer | D · To issuer | — | −158,371 | 0 | -100% | — | ||
| Sep 3, 202616:39 | Sep 3, 2026 | APGE | Chief Executive Officer, Director | D · To issuer | — | −920,941 | 0 | -100% | — | ||
| Sep 3, 202616:39 | Sep 3, 2026 | APGE | Director | D · To issuer | $135.11 | −1,750,000 | 0 | -100% | $236.4M | ||
| Aug 11, 202616:30 | Aug 7, 2026 | APGE | Director · +3 joint | M · Exercise | $23.60 | +42,208 | 340,855 | +14% | $996K | ||
| Aug 7, 202620:00 | Aug 5, 2026 | APGE | Chief Medical Officer | S · Sell10b5-1 | $134.17 | −5,500 | 168,498 | -3% | −$738K | ||
| Aug 7, 202620:00 | Aug 5, 2026 | APGE | Chief Medical Officer | M · Exercise10b5-1 | $22.86 | +4,125 | 173,998 | +2% | $94K |